Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:Q06643 (
non-Hodgkin's lymphoma
)
11,307
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Thymidine kinase (TK) isoenzymes and thymidine phosphorylase (TP) activities have been measured in peripheral mononuclear cells of patients with acute lymphoblastic and monoblastic leukaemia or B-chronic lymphocytic leukaemia, as well as in normal subjects, and also in lymph node cells from patients with
non-Hodgkin's lymphoma
, with Hodgkin's disease and with benign adenopathies. TK1 isoenzyme activity was highest in acute lymphoblastic leukaemia and in centroblastic lymphoma. Then in progressively decreasing order appeared the Hodgkin's disease values, the centroblastic centrocytic lymphoma values and the benign reactive lymph node cell values. When compared to normal blood mononuclear cells, TP was greatly decreased in acute lymphoblastic leukaemia and slightly but significantly decreased in chronic leukaemia. Monoblastic cells exhibited a unique enzyme pattern; moderately increased TK1 activity and high TP activity. Our results suggest that both enzymes are indicative of the maturation status of leukaemic cells from B lineage. They demonstrate that in lymph node cells, TK1 reflects the proliferative status of both malignant and non-malignant cells and that in monoblastic cells the synthesis of
dTMP
through de novo synthesis is favoured.
...
PMID:Thymidine kinase and thymidine phosphorylase activities in various types of leukaemia and lymphoma. 653
Nocardiosis is an opportunistic infection especially in immunocompromised patients. Lungs are the most common infection sites and therapy poses some difficulties. We describe a case of pulmonary infection with Nocardia asteroides in a
non-Hodgkin's lymphoma
patient. Although the mortality from pulmonary nocardiosis is high in immunocompromised patients, our patient was successfully treated with trimethoprim-sulfamethoxazole (
TMP
/SMZ) and amikacin. Maintenance therapy with
TMP
/SMZ was continued for 1 year. This case supports the importance of the long-term maintenance treatment after the initial combination therapy.
...
PMID:Pulmonary nocardiosis in a non-Hodgkin's lymphoma patient. 1223 71
We describe a 58-year-old patient with relapsing high-grade
non-Hodgkin's lymphoma
who exhibited exacerbation of posthypoxic action myoclonus during high-dose intravenous trimethoprim-sulfamethoxazole (TMP-SMX) treatment for highly suspicious Pneumocystis jiroveci pneumonia (PCP). Three months previously the patient had experienced a hypoxic insult caused by respiratory arrest due to an anaphylactic reaction to antibiotic therapy. He had developed posthypoxic action myoclonus (Lance-Adams syndrome), which was well controlled by oral treatment with piracetam. However, after
TMP
-SMX therapy (115 mg/kg daily) was started for suspicion of newly developed PCP, posthypoxic action myoclonus worsened dramatically resulting in complete disability. Anti-myoclonic therapy with increased doses of piracetam and valproic acid did not significantly improve his clinical condition. Only when TMPSMX doses were reduced (38 mg/kg daily) on day 12 did action myoclonus cease within 2 to 3 days. We suggest that
TMP
-SMX can exacerbate posthypoxic action myoclonus.
...
PMID:Trimethoprim-sulfamethoxazole exacerbates posthypoxic action myoclonus in a patient with suspicion of Pneumocystis jiroveci infection. 1518 79